Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 2.2 EX-2.2
- 5.1 EX-5.1
- 8.1 EX-8.1
- 8.2 EX-8.2
- 10.54 EX-10.54
- 10.55 EX-10.55
- 10.56 EX-10.56
- 10.57 EX-10.57
- 10.58 EX-10.58
- 10.59 EX-10.59
- 10.60 EX-10.60
- 10.61 EX-10.61
- 10.62 EX-10.62
- 10.63 EX-10.63
- 10.64 EX-10.64
- 10.65 EX-10.65
- 10.66 EX-10.66
- 10.67 EX-10.67
- 10.68 EX-10.68
- 10.69 EX-10.69
- 10.70 EX-10.70
- 10.71 EX-10.71
- 10.72 EX-10.72
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
ANIP similar filings
- 26 Apr 13 Registration of securities issued in business combination transactions
- 18 Jan 13 Registration of securities issued in business combination transactions (amended)
- 11 Dec 12 Registration of securities issued in business combination transactions
- 19 Aug 09 Registration of securities issued in business combination transactions (amended)
- 7 Aug 09 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-4 of our report dated March 13, 2012 (December 11, 2012 as to the effects of the reverse stock split described in Note 2) relating to the financial statements of BioSante Pharmaceuticals, Inc. and our report dated March 13, 2012 relating to the effectiveness of BioSante Pharmaceuticals, Inc.’s internal control over financial reporting, appearing in the joint proxy statement/prospectus, which is part of this Registration Statement.
We also consent to the reference to us under the heading “Experts” in such joint proxy statement/prospectus.
/s/ DELOITTE & TOUCHE LLP
Chicago, Illinois
December 11, 2012